FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044201404> ?p ?o ?g. }

• W2044201404 endingPage "2457" @default.
• W2044201404 startingPage "2453" @default.
• W2044201404 abstract "The present study evaluated the efficacy and safety of pemetrexed, carboplatin and bevacizumab, followed by maintenance pemetrexed and bevacizumab, in chemotherapy-naïve patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC). The patients were administered pemetrexed (500 mg/m2), carboplatin (area under the concentration-time curve, 6.0 mg/ml × min) and bevacizumab (15 mg/kg) intravenously every three weeks for up to six cycles. Patients who did not experience tumor progression remained on maintenance pemetrexed and bevacizumab until disease progression or unacceptable toxicity occurred. The primary endpoint was the overall response rate. Of the 26 patients enrolled between March 2010 and April 2011, three were excluded due to brain metastases, therefore the intention-to-treat (ITT) population consisted of 23 patients. The median age was 64 years (range, 40-74 years) and 15 patients were male. In total, six patients had a performance status of 0, and 20 had stage IV tumors. The response rate was 69.6% [95% confidence interval (CI), 47.1-86.8], the disease control rate was 100% and the time to response was 1.2 months (95% CI, 0.72-1.93). The median progression-free survival time was 8.6 months (95% CI, 5.9-10.9) and the median overall survival time was 18.6 months (95% CI, 12.9-24.8). There were no grade 3 or worse hemorrhagic events and the feasibility was modest. Overall, pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab, was effective and tolerable in the patients with non-squamous NSCLC, and the time to response was relatively short." @default.
• W2044201404 created "2016-06-24" @default.
• W2044201404 creator A5005318923 @default.
• W2044201404 creator A5006336889 @default.
• W2044201404 creator A5007061097 @default.
• W2044201404 creator A5027644769 @default.
• W2044201404 creator A5029364562 @default.
• W2044201404 creator A5029865286 @default.
• W2044201404 creator A5034172526 @default.
• W2044201404 creator A5039896704 @default.
• W2044201404 creator A5049526717 @default.
• W2044201404 creator A5063354711 @default.
• W2044201404 creator A5063817865 @default.
• W2044201404 creator A5067399580 @default.
• W2044201404 creator A5072177616 @default.
• W2044201404 creator A5072367324 @default.
• W2044201404 date "2014-09-19" @default.
• W2044201404 modified "2023-09-27" @default.
• W2044201404 title "Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer" @default.
• W2044201404 cites W1967947451 @default.
• W2044201404 cites W1969328947 @default.
• W2044201404 cites W1970015742 @default.
• W2044201404 cites W1974165456 @default.
• W2044201404 cites W1979101646 @default.
• W2044201404 cites W1989664813 @default.
• W2044201404 cites W2005244154 @default.
• W2044201404 cites W2020830322 @default.
• W2044201404 cites W2037139573 @default.
• W2044201404 cites W2043696829 @default.
• W2044201404 cites W2060251426 @default.
• W2044201404 cites W2076668534 @default.
• W2044201404 cites W2084740377 @default.
• W2044201404 cites W2099725888 @default.
• W2044201404 cites W2109134893 @default.
• W2044201404 cites W2111179508 @default.
• W2044201404 cites W2139248078 @default.
• W2044201404 cites W2139675556 @default.
• W2044201404 cites W2144660856 @default.
• W2044201404 cites W2145835533 @default.
• W2044201404 cites W2148367564 @default.
• W2044201404 cites W2151090489 @default.
• W2044201404 cites W2158743409 @default.
• W2044201404 cites W2626223149 @default.
• W2044201404 cites W4239714259 @default.
• W2044201404 doi "https://doi.org/10.3892/ol.2014.2552" @default.
• W2044201404 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4214444" @default.
• W2044201404 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25364406" @default.
• W2044201404 hasPublicationYear "2014" @default.
• W2044201404 type Work @default.
• W2044201404 sameAs 2044201404 @default.
• W2044201404 citedByCount "10" @default.
• W2044201404 countsByYear W20442014042015 @default.
• W2044201404 countsByYear W20442014042016 @default.
• W2044201404 countsByYear W20442014042017 @default.
• W2044201404 countsByYear W20442014042018 @default.
• W2044201404 countsByYear W20442014042020 @default.
• W2044201404 countsByYear W20442014042021 @default.
• W2044201404 crossrefType "journal-article" @default.
• W2044201404 hasAuthorship W2044201404A5005318923 @default.
• W2044201404 hasAuthorship W2044201404A5006336889 @default.
• W2044201404 hasAuthorship W2044201404A5007061097 @default.
• W2044201404 hasAuthorship W2044201404A5027644769 @default.
• W2044201404 hasAuthorship W2044201404A5029364562 @default.
• W2044201404 hasAuthorship W2044201404A5029865286 @default.
• W2044201404 hasAuthorship W2044201404A5034172526 @default.
• W2044201404 hasAuthorship W2044201404A5039896704 @default.
• W2044201404 hasAuthorship W2044201404A5049526717 @default.
• W2044201404 hasAuthorship W2044201404A5063354711 @default.
• W2044201404 hasAuthorship W2044201404A5063817865 @default.
• W2044201404 hasAuthorship W2044201404A5067399580 @default.
• W2044201404 hasAuthorship W2044201404A5072177616 @default.
• W2044201404 hasAuthorship W2044201404A5072367324 @default.
• W2044201404 hasBestOaLocation W20442014041 @default.
• W2044201404 hasConcept C126322002 @default.
• W2044201404 hasConcept C141071460 @default.
• W2044201404 hasConcept C143998085 @default.
• W2044201404 hasConcept C2776256026 @default.
• W2044201404 hasConcept C2776694085 @default.
• W2044201404 hasConcept C2777240266 @default.
• W2044201404 hasConcept C2777802072 @default.
• W2044201404 hasConcept C2778239845 @default.
• W2044201404 hasConcept C2781451048 @default.
• W2044201404 hasConcept C31760486 @default.
• W2044201404 hasConcept C71924100 @default.
• W2044201404 hasConceptScore W2044201404C126322002 @default.
• W2044201404 hasConceptScore W2044201404C141071460 @default.
• W2044201404 hasConceptScore W2044201404C143998085 @default.
• W2044201404 hasConceptScore W2044201404C2776256026 @default.
• W2044201404 hasConceptScore W2044201404C2776694085 @default.
• W2044201404 hasConceptScore W2044201404C2777240266 @default.
• W2044201404 hasConceptScore W2044201404C2777802072 @default.
• W2044201404 hasConceptScore W2044201404C2778239845 @default.
• W2044201404 hasConceptScore W2044201404C2781451048 @default.
• W2044201404 hasConceptScore W2044201404C31760486 @default.
• W2044201404 hasConceptScore W2044201404C71924100 @default.
• W2044201404 hasIssue "6" @default.
• W2044201404 hasLocation W20442014041 @default.
• W2044201404 hasLocation W20442014042 @default.

• next